Peptide hydrogels are water-rich gels built from short peptides, either peptides that assemble themselves into a mesh or gels carrying a peptide that helps cells attach. They can fill a wound, seal a cut, or release a drug slowly in one spot.
The site's coverage so far is animal research. In October 2026, a University of Osaka team with device maker Menicon reported that the self-assembling peptide gel SPG-178 sealed the cut pancreas better than standard mesh and fibrin glue in rats. A Wenzhou Medical University group used an injectable peptide gel to release an anti-scarring compound in the uterus, restoring pregnancy rates in rats with intrauterine adhesions. A Shanghai Ocean University gel containing the cell-adhesion peptide RGD closed 96% of skin wounds by day 14 in mice.
See #drug-delivery and #preclinical.
Researchers at IIT Bombay and Mumbai's Institute of Chemical Technology built an injectable hydrogel from functional amyloid peptides that kept insulin stable and released it over 90 hours in lab tests. One injection under the skin brought diabetic rats' glucose to normal within 30 minutes and held it for 60 hours before it rose again at 66 hours, far longer than free insulin. Adding sodium alginate let the team tune the release rate.
The Exos@TRM gel builds on the self-assembling RADA16 peptide, adds a TGF-β1-binding peptide and a stem cell-recruiting motif, and releases bone marrow stem cell exosomes for about a week. In rats with surgically made cartilage-and-bone defects, it cut inflammatory M1 macrophages, drew in the animals' own TGF-β1 and stem cells, and formed tissue resembling natural cartilage. The authors note the acute surgical model does not mirror chronic human cartilage wear.
Researchers at Kazan Federal University in Russia reported in Macromolecular Bioscience on October 21, 2026 a macroporous, multi-channel hydrogel scaffold made from oligo(poly(ethylene glycol) fumarate) and coated with four signaling peptides, IKVAV, RGD, GHK, and LRE, intended to bridge a completely severed spinal cord without added cells or growth factors. The peptide mix promoted nerve-cell growth in culture, and in a pilot study in minipigs with a cut spinal cord the implant integrated with tissue, kept its structure, and was infiltrated by host cells. The pilot looked at short-term integration, not recovery of movement.
Researchers at Shanghai Ocean University reported in Molecules on October 19, 2026 that a carboxymethyl chitosan gel combined with hyaluronic acid and RGD, a short cell-adhesion peptide, curbed bacterial growth, reduced bleeding, and sped healing of full-thickness skin wounds in mice. Wound closure reached 95.56% by day 14 compared with 79.85% for the base gel, with denser collagen and lower inflammatory signals. The results are from mice.
University of Osaka surgeons, with co-authors from Japanese medical device maker Menicon, reported in Scientific Reports on October 15, 2026 a rat study of SPG-178, a self-assembling peptide hydrogel, to prevent pancreatic fistula, a leak of pancreatic fluid that often follows pancreas surgery. Three days after the pancreas was cut, fluid amylase, a marker of leakage, averaged 109 IU/L with SPG-178, compared with 283 in untreated rats and 219 with the standard polyglycolic acid mesh and fibrin glue, and the gel group had fewer adhesions and less tissue damage. Human testing has not been reported.
Researchers at the First Affiliated Hospital of Wenzhou Medical University reported in ACS Applied Materials & Interfaces on October 15, 2026 an injectable, biodegradable peptide hydrogel that slowly releases puerarin, an anti-scarring plant compound, inside the uterus. In rats with intrauterine adhesions, scar tissue that is a leading cause of infertility, the gel acted as a physical barrier, restored the uterine lining's glands and blood vessels, reduced fibrosis, and markedly raised pregnancy rates. The results are from rats.